Combination of vibostolimab and pembrolizumab is well tolerated and has antitumor activity.

中文翻译：

---

具有 PD-1 抑制剂的抗 TIGIT 抗体在实体瘤中显示出前景

vibostolimab 和 pembrolizumab 的组合具有良好的耐受性并具有抗肿瘤活性。